1. EMD121974 (NSC 707544, cilengitide) in asymptomatic metastatic androgen independent prostate cancer (AIPCa) patients (pts): a randomized trial by the Prostate Cancer Clinical Trials Consortium (NCI 6372);Bradley;J Clin Oncol,2007
2. Carducci MA, Morris MJ, Eisenberger MA, et al. Phase 1 dose-escalation study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer. Presented at: the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 22-26, 2007; San Francisco, CA. Abstract A62.
3. Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): a phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862);Hussain;J Clin Oncol,2007
4. Oh WK, Jacobus S, Ross R, et al. A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy. Presented at: the 2007 Prostate Cancer Symposium; December 22-24, 2007; Orlando, FL. Abstract 238.
5. Zurita AJ, Shore N, Kozloff M, et al. Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC). Presented at: the 2007 Prostate Cancer Symposium; February 22-24, 2007; Orlando, FL. Abstract 230.